Comparison of the in vivo pharmacokinetics and in vitro dissolution of raltegravir in HIV patients receiving the drug by swallowing or by chewing

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 12, 2012, Pages 6132-6136

  Cattaneo, Dario ^a,b   Baldelli, Sara ^a,b   Cerea, Matteo ^c   Landonio, Simona ^a   Meraviglia, Paola ^a   Simioni, Emanuela ^a   Cozzi, Valeria ^a   Fucile, Serena ^a   Gazzaniga, Andrea ^c   Clementi, Emilio ^a,d   Galli, Massimo ^a   Rizzardini, Giuliano ^a   Gervasoni, Cristina ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b CNR   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d SCIENTIFIC INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

RALTEGRAVIR;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CHEWABLE TABLET; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; PH; PRIORITY JOURNAL; SWALLOWING;

ADMINISTRATION, ORAL; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; AREA UNDER CURVE; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DEGLUTITION; FEMALE; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HUMANS; MALE; MASS SPECTROMETRY; MASTICATION; MIDDLE AGED; PYRROLIDINONES; SOLUBILITY; TABLETS; TASTE;

EID: 84869219884     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00942-12     Document Type: Article

References (17)

1. Arab-Alameddine M, et al. 2012. Population pharmacokinetic analysis and pharmacogenetics of raltegravir In HIV-positive and healthy individuals. Antimicrob. Agents Chemother. 56:2959-2966.
2. Brainard DM, Wenning LA, Stone JA, Wagner JA, Iwamoto M. 2011. Clinical pharmacology profile of raltegravir, an HIV-1 integrase strand transfer inhibitor. J. Clin. Pharmacol. 51:1376-1402.
3. Carey D, et al. 2012. A randomized study of pharmacokinetics, efficacy and safety of two raltegravir plus atazanavir strategies in ART-treated adults. J. Acquir. Immune Defic. Syndr. 60:143-149.
4. Cattaneo D, et al. 2012. Inter- and intra-patient variability of raltegravir pharmacokinetics in HIV-1-infected subjects. J. Antimicrob. Chemother. 67:460-464.
5. Cattaneo D, et al. 2012. Limited sampling strategies for the estimation of raltegravir daily exposure in HIV-Infected patients. J. Clin. Pharmacol. 52:440-445.
6. Davis SS. 1985. The design and evaluation of controlled release systems for the gastrointestinal tract. J. Control Release 2:27-38.
7. Eron JJ, et al. 2010. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet 375:396-407.
8. Eron JJ, Jr, et al. 2011. Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. Lancet Infect. Dis. 11:907-915.
9. Fayet A, et al. 2009. A LC-tandem MS assay for the simultaneous measurement of new antiretroviral agents: raltegravir, maraviroc, darunavir, and etravirine. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 877:1057-1069.
10. FDA. 5 July 2011 access date. FDA guidance for industry 2001 - bioanalytical method validation. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm070107.pdf.
11. Garrido C, et al. 2012. Plasma raltegravir exposure influences the antiviral activity and selection of resistance mutations. AIDS Res. Hum. Retroviruses 28:156-164.
12. Kozal MJ, et al. 2010. The SPARTAN Study: a pilot study to assess the safety and efficacy of an investigational NRTI and RTV-sparing regimen of atazanavir experimental dose of 300 mg bid plus raltegravir 400 mg bid in treatment naïve HIV-infected patients, abstr THL BB204, p 286. Abstr. 18th Int. AIDS Conf., Vienna, Austria. International AIDS Society, Geneva, Switzerland.
13. Rizk ML, et al. 2012. Pharmacokinetics and pharmacodynamics of once-daily versus twice-daily raltegravir in treatment-naive HIV-infected patients. Antimicrob. Agents Chemother. 56:3101-3106.
14. Steigbigel RT, et al. 2008. Raltegravir with optimized background therapy for resistant HIV-1 infection. N. Engl. J. Med. 359:339-354.
15. Taiwo B, et al. 2011. Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naïve HIV-1-infected patients (ACTG A5262). AIDS 25:2113-2122.
16. Wenning L, et al. 2008. Pharmacokinetic/pharmacodynamic analyses for raltegravir in phase II and III studies in treatment experienced HIV-infected patients, abstr. OA25, p. 56. Abstr. 9th Int. Workshop Clin. Pharmacol. HIV Ther., New Orleans, LA. Virology Education, Utrecht, The Netherlands.
17. Wenning LA, et al. 2009. Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphisms. Clin. Pharmacol. Ther. 85:623-627.